PT  - JOURNAL ARTICLE
AU  - Guido España
AU  - Zulma M. Cucunubá
AU  - Juliana Cuervo-Rojas
AU  - Hernando Díaz
AU  - Manuel González-Mayorga
AU  - Juan David Ramírez
TI  - The potential impact of delta variant of SARS-CoV-2 in the context of limited vaccination coverage and increasing social mixing in Bogotá, Colombia
AID  - 10.1101/2021.08.06.21261734
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.06.21261734
4099  - http://medrxiv.org/content/early/2021/08/07/2021.08.06.21261734.short
4100  - http://medrxiv.org/content/early/2021/08/07/2021.08.06.21261734.full
AB  - Background More than 122,000 COVID-19 associated deaths have been reported in Colombia and about 27,000 in the city of Bogotá by the first week of August, with vaccination coverage in the city at 30% for complete schemes and at 37% for partial vaccination. As the incidence of cases currently decreases, questions remain about the potential impact of the delta variant already present in the city.Methods We used an agent-based model calibrated to data on age-structured deaths and dominance of variants in Bogotá. We used efficacy data for the portfolio of vaccines available, including known changes for SARS-CoV-2 variants. We modelled scenarios of early and delayed introduction of the delta variant in the city along with changes in mobility and social contact, and vaccine strategies over the next months.Findings We estimate that by mid July, vaccination may have already prevented 17,800 (95% CrI: 16,000 - 19,000) deaths in Bogotá. The delta variant could become dominant and lead to a fourth wave later in the year, but its timing will depend on the date of introduction, social mixing patterns, and vaccination strategy. In all scenarios, higher social mixing is associated with a fourth wave of considerable magnitude. If an early delta introduction occurred (dominance by mid July), a new wave may occur in August/September and in such case, age prioritization of vaccination and second dose not postponed are more important. However, if introduction occurred one or two months later (dominance by mid August/September) the age-prioritization is less relevant but maintaining the dose scheme without postponement is more important. In all scenarios we found that increasing the vaccination rate from the current average of 50,000/day to 100,000/day reduces the impact of a fourth wave due to the delta variant.Conclusions In Bogotá, the delta variant could still lead to a fourth wave, whose magnitude would depend on its introduction time and the level of social mixing. Its impact can be mitigated by increasing vaccination rates to achieve high coverage quickly, with non-delayed second doses. We found that, at this point, suspending the age prioritization to achieve higher coverage with first doses does not seem to have a major effect on deaths and ICU demand. But, delaying the second dose may not be beneficial and may even increase the incidence of severe outcomes.Competing Interest StatementZMC and GE are ad honorem members of the Scientific Advisory Group on epidemiological modeling at Secretaría de Salud of Bogotá. MGM holds a decision making position at Secretaría de Salud of BogotáFunding StatementGE received funding from an NSF RAPID grant (DEB 2027718). HD received partial funding from the National University of Colombia (Universidad Nacional de Colombia (HERMES 50419)). ZMC receives funding from the Medical Research Council (MR/R024855/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval by Comite de Investigaciones y Etica Institucional - CIEI, Facultad de Medicina Pontificia Universidad Javeriana - Hospital Universitario San Ignacio on session 13 May 2021 (Approval number 08-21), project ref 2021-109.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this project is publicly available. The code of this project can be accessed on https://github.com/confunguido/FRED https://github.com/confunguido/FRED